VU0155041

• Catalog No.: V1640
• M. F.: C14H15Cl2NO3
• M. W.: 316.1798
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
• IUPAC Traditional name: (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
• Synonyms: (±)-cis-2-(3,5-Dicholorphenylcarbamoyl)cyclohexanecarboxylic acid

DATABASE IDS

• MDL Number: MFCD03544581

PROPERTIES

• Empirical Formula (Hill Notation): C14H15Cl2NO3
• Purity: ≥98% (HPLC)
• Apperance: white powder
• Solubility: DMSO: soluble54 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H302
• European Hazard Symbols: Harmful (Xn)
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves
• Risk Statements: 22
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
VU0155041 is a mixed allosteric agonist/positive allosteric modulator (PAM) of mGluR4. VU0155041 is approximately 8-fold more potent than PHCCC and does not show any significant potentiator or antagonist activity at other mGluR subtypes. It is soluble in an aqueous vehicle and intracerebroventricular administration of 31-316 nmol of VU0155041 dose-dependently decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats. VU0155041 exhibits selectivity for mGluR4 relative to 67 different targets and does not affect the function of striatal NMDA receptors.
VU0155041 is a positive allosteric modulator of the metabotropic glutamate receptor subtype 4. It also shows some direct agonist activity, but at a site different from the glutamate binding site. /VU0155041 is approximately 8-fold more potent than PHCCC and enhances the activity of glutamate also about 8-fold. It shows promising anti-Parkinsonian effects in animal models of Parkinson′s disease.

Description (简体中文)

Biochem/physiol Actions
VU0155041 is a mixed allosteric agonist/positive allosteric modulator (PAM) of mGluR4. VU0155041 is approximately 8-fold more potent than PHCCC and does not show any significant potentiator or antagonist activity at other mGluR subtypes. It is soluble in an aqueous vehicle and intracerebroventricular administration of 31-316 nmol of VU0155041 dose-dependently decreased haloperidol-induced catalepsy and reserpine-induced akinesia in rats. VU0155041 exhibits selectivity for mGluR4 relative to 67 different targets and does not affect the function of striatal NMDA receptors.
VU0155041 is a positive allosteric modulator of the metabotropic glutamate receptor subtype 4. It also shows some direct agonist activity, but at a site different from the glutamate binding site. /VU0155041 is approximately 8-fold more potent than PHCCC and enhances the activity of glutamate also about 8-fold. It shows promising anti-Parkinsonian effects in animal models of Parkinson′s disease.